The combination of a recently approved blood test for detection of Alzheimer's disease combined with two medications that ...

Roche is focusing on early diagnosis of Alzheimer's disease and will soon release its first blood-based biomarker for the ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the latest findings on lecanemab (Leqembi®), including four-year efficacy and safety data and data on the subcutaneous ...

Globally, it is estimated that someone develops dementia every three seconds, and the number of people living with dementia is expected to reach 78 million by 2030.The progressive neurodegenerative ...

Lecanemab presentations to include long-term Clarity AD data, real-world treatment insights, and a subcutaneous formulation ...

With few treatments available to treat Alzheimer’s disease, scientists have turned to cancer drugs as a potential means of ...

Dr. Ausim Azizi is among those seeing the overall early results, as Yale New Haven Hospital is in the forefront of research ...

Leqembi is the first FDA-approved drug shown to slow the progression of early-stage Alzheimer’s. Medi-Cal can cover Leqembi ...